Healthcare major Roche (OTCMKTS:RHHBY) reported that its Q1 2022 group sales rose 11% year-over-year on a constant currency basis to CHF 16.45 billion (about $17.7 billion).
Growth was driven by the diagnostics division, which saw robust demand for Covid-19 tests and a recovery in the base business. The pharma division grew by about 6%.
However, the company sees a slowdown in Covid-19 driven sales growth. For the full year, it expects that total sales could grow in the low-single digits in constant currency terms while guiding for adjusted earnings growth in the low to mid-single-digit range.
|S&P 500 Return||-6%||-10%||91%|
|Trefis Multi-Strategy Portfolio||-6%||-13%||243%|
 Month-to-date and year-to-date as of 4/26/2022
 Cumulative total returns since the end of 2016